文献速递疼痛医学

HTX-011的作用机制:一种新型缓释双作用局部麻醉制剂用于术后疼痛

Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain.
PubMed 文献 · Reg Anesth Pain Med · 2019-12-16

该研究通过临床前猪模型和II期拇囊炎切除术试验,探讨HTX-011(布比卡因与低剂量美洛昔康组成的缓释双作用局麻药)的作用机制。临床前数据显示HTX-011可降低切口组织酸性,使组织pH正常化,从而增强并延长镇痛活性;II期试验中,HTX-011在术后72小时内镇痛效果优于聚合物中各单组分。结论认为低剂量美洛昔康通过正常化局部pH产生协同镇痛作用。

要点

  • HTX-011通过低剂量美洛昔康正常化切口局部pH,增强布比卡因镇痛活性。
  • 临床前猪模型显示HTX-011减轻组织炎症酸性,与镇痛增强和延长相关。
  • II期拇囊炎试验中HTX-011术后72小时镇痛优于聚合物中各单组分。

核心结论

  • 临床前动物和临床结果证实HTX-011中低剂量美洛昔康正常化切口局部pH,相比缓释布比卡因产生更优的协同镇痛活性。
  • HTX-011是一种具有双作用机制的缓释局麻药,可能为术后疼痛治疗提供重要进展。

研究设计与样本

  • 临床前研究采用经验证的术后疼痛猪模型,评估HTX-011、口服美洛昔康、脂质体布比卡因和生理盐水安慰剂的镇痛效果。
  • 临床部分为II期拇囊炎切除术试验(注册号NCT02762929),评估HTX-011与聚合物中各单组分的镇痛效果。

主要发现

  • 临床前数据显示HTX-011能减轻局部组织炎症,表现为组织pH酸性降低,并与镇痛活性增强和延长相关。
  • II期拇囊炎研究中,HTX-011在术后72小时内实现优于聚合物中各单组分的持续疼痛缓解。

关键数值与推荐

  • 临床前评估了HTX-011中美洛昔康与布比卡因的最佳比例及HTX-011对切口组织pH的影响。
  • II期试验主要比较HTX-011与聚合物中各单组分的术后72小时镇痛效果。

临床怎么用

  • HTX-011通过双作用机制(pH正常化+缓释布比卡因)可能延长术后镇痛时间至72小时。
  • 该机制提示联合低剂量美洛昔康可增强局麻药在炎症组织中的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Obtaining consistent efficacy beyond 12-24 hours with local anesthetics, including extended-release formulations, has been a challenging goal. Inflammation resulting from surgery lowers the pH of affected tissues, reducing neuronal penetration of local anesthetics. HTX-011, an investigational, nonopioid, extended-release dual-acting local anesthetic combining bupivacaine and low-dose meloxicam, was developed to reduce postsurgical pain through 72 hours using novel extended-release polymer technology. Preclinical studies and a phase II clinical trial were conducted to confirm the mechanism of action of HTX-011. METHODS: In a validated postoperative pain pig model and a phase II bunionectomy trial, the analgesic effects of HTX-011, oral meloxicam (preclinical only), liposomal bupivacaine (preclinical only) and saline placebo were evaluated. The optimal meloxicam:bupivacaine ratio for HTX-011 and the effect of HTX-011 on incisional tissue pH were also evaluated preclinically. RESULTS: Preclinical data demonstrate the ability of HTX-011 to address local tissue inflammation as demonstrated by a less acidic tissue pH, which was associated with potentiated and prolonged analgesic activity. In the phase II bunionectomy study, HTX-011 achieved superior and sustained pain relief through 72 hours after surgery compared with each component in the polymer. CONCLUSIONS: Preclinical animal and clinical results confirm that the low-dose meloxicam in HTX-011 normalizes the local pH in the incision, resulting in superior and synergistic analgesic activity compared with extended-release bupivacaine. HTX-011 represents an extended-release local anesthetic with a dual-acting mechanism of action that may provide an important advancement in the treatment of postoperative pain. TRIAL REGISTRATION NUMBER: NCT02762929.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Ottoboni T, Quart B, Pawasauskas J, et al. Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain. Reg Anesth Pain Med. 2019. PMID: 31843865. doi:10.1136/rapm-2019-100714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。